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In 1975, when Kohler and Milstein generated hybridoma
cells that produced unlimited amounts of mouse monoclo-
nal antibodies (mAbs) that recognized speciﬁc antigenic
determinants, the diagnostic and therapeutic implications of
the discovery were recognized immediately [1]. A decade
later, the ﬁrst well-characterized mAb, OKT3 [2], was
approved as therapy for acute organ rejection in humans,
and since then the development of therapeutic mAbs has
progressed at an unrelenting pace as a result of improved
technological advances. Now, mAbs, also known as ‘biologi-
cals’, constitute one of the fastest-growing classes of therapeu-
tic agent, with over 30 molecules approved by the Food and
Drug Administration and on the market. In recent years,
their use has revolutionized the treatment and prevention of
a broad range of human illnesses (cancers, inﬂammatory and
autoimmune diseases, and solid organ transplant rejection),
and it is easy to predict that their therapeutic indications will
expand widely in the near future. Hundreds of mAbs with
improved bioactivity are currently in the pipeline, at various
phases of clinical developmen; and it is because of their rapid
development that it should always be remembered that
mAbs have only recently been added to the list of drugs
approved for clinical use, and the investigation of their effects
may be fraught with difﬁculty. Carefully controlled studies
are needed for the full determination of their therapeutic
and research potential. If we focus on their main features,
such as therapeutic efﬁcacy, a broad range of potential clini-
cal applications, and the possibility of treating/curing patients
with very poor prognoses, it becomes clear that mAbs have
gone from being difﬁcult-to-develop molecules to today’s
‘successful drugs’ at the front line of advanced therapeutic
medicine.
However, the therapeutic use of mAbs is still in its
infancy. Indeed, the overall picture of the phenomena
induced by the complex interactions of these new molecules
with various components of immunity is far from clear, and
needs to be pieced together carefully, thus providing fertile
research ground for the evaluation of, at the very least, the
advantages and disadvantages of treatment. Depending on
the disease to be treated and on their speciﬁcity, mAbs
engage different extracellular targets (i.e. soluble ligands,
membrane-bound proteins, and cytokines) and, as a conse-
quence, extensively modulate various signalling pathways.
Our understanding of some of these targets is limited, and
the effects of the perturbation of such pathways on the
immune response are still poorly understood. It is very clear,
however, that mAbs do not limit their actions to their
target(s), but stimulate, to some degree, several immune
pathways that may perturb the control mechanisms of recog-
nition and defence against exogenous and endogenous patho-
gens. This is important because of the increasing likelihood,
as reported above, of their being used to treat and/or cure
an ever-increasing number of diseases. Most will necessarily
lead to prolonged treatment, thus creating favourable condi-
tions for reactivation of endogenous infection or inefﬁcient
containment of host invasion by exogenous pathogens. It is
therefore inevitable that the effects and side effects that are
currently known to be induced by mAbs may constitute only
a small proportion of those that we will become aware of as
the prolonged use of certain mAbs becomes routine.
Combining the above considerations with what we know
about the potential immunosuppressive impact of mAb ther-
apy, it is clear that a Theme Section covering aspects of this
stimulating area of research is not only warranted but raises
our expectations. However, the minireviews that follow inev-
itably discuss only a limited number of aspects of the subject,
merely scratching the surface of the problem, and warning
the reader that many investigations to date deal almost
exclusively with a very limited number of mAbs or a limited
number of patients. However, the thrust of all the articles
should stimulate enough scientiﬁc curiosity for additional
research on those many aspects of mAb therapy still requir-
ing elucidation.
The papers presented here review various important
aspects of work on mAbs. Focosi et al. [3] summarize the
problems associated with the development of current and
next-generation mAbs, pointing out the need to understand
fully the infective risk associated with their therapeutic use.
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Gentile and Foa` review the clinical impact of the use of
mAbs in patients, describing the main clinically relevant viral
infections associated with each individual mAb [4]. Khalili
et al. consider the epidemiological and clinical data relating to
the occurrence of progressive multifocal leukoencephalopa-
thy (PML) as a complication of the use of mAbs in patients
with autoimmune diseases [5]. Finally, Cavallo [6] highlights
the role of the clinical virology laboratory in monitoring
patients undergoing mAb therapy.
In addition to these practical aspects, the mAbs issue
offers a unique research opportunity. Somewhat unexpect-
edly, we are learning a great deal from the clinical use of
mAbs. First, the increasing incidence of once rare diseases in
patients treated with mAbs provides a unique opportunity to
cast light on the pathogenetic mechanisms and clinical rele-
vance in humans of such diseases. A typical example is the
above-mentioned PML, a rare, rapidly fatal, demyelinating dis-
ease of the brain that, in the past, was mostly regarded as a
major complication in human immunodeﬁciency virus-positive
patients; it is now a serious side effect of some new mAbs
that has curbed initial enthusiasm and led to mounting con-
cerns about their use in a clinical setting. The growing num-
ber of PML cases seen in those being treated with rituximab
or natalizumab, two of the most popular and widely used
mAbs, has proved to be such an invaluable source of new
information that an extensive revision has started of what
were considered to be clearly established clinical and patho-
genetic features of the disease. Second, microbiologists are
taking advantage of the pleiotropic effects of mAbs on the
immune system to decipher many aspects of the biology and
life cycle of some opportunistic pathogens. Again, PML is a
good example. Among the various features decoded, the
upregulation of several cellular components induced by mAbs
has allowed the deﬁnition of some host cell factors that pro-
mote the replication of the JC virus (JCV), the aetiological
agent of PML. Also, perturbation of normal cell homeostasis
has revealed the active role of cell-mediated immunity in
restraining JCV replication in the brain. This is most impor-
tant, as it was considered that the immune system exerted
only loose control on the central nervous system and that
JCV, which was believed to reactivate only after profound
immunosuppression, is actively monitored and repressed by
brain immune effectors. Because of this, the host cell–JCV
interplay and, broadly speaking, the reassessment of knowl-
edge and dogmas of immune system efﬁciency and function
within a body’s compartment are objects of intense research.
It follows that investigational approaches and the deﬁnition
of biomarkers to predict the re-emergence of JCV infection
during mAb treatment are also under scrutiny.
Finally, if mAbs quickly become potent tools for treating a
variety of chronic diseases, the study of the multifaceted bio-
logical effects modulated by their in vivo administration is an
exciting new area for the scientiﬁc community to search for
information that will lead to a better understanding of
microbe–host relationships, and the role and function of
innate and adaptive responses to self-molecules and non-self-
molecules.
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